Metropolitan Life Insurance Company (MetLife)’s Pliant Therapeutics PLRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,049	Closed	-$45.4K	–	1571
2024 Q1	$45.4K	Sell	3,049 -429	-12%	-$7.08K	﹤0.01%	1453
2023 Q4	$63K	Hold	3,478	–	–	﹤0.01%	1319
2023 Q3	$60.3K	Buy	3,478 +389	+13%	+$6.74K	﹤0.01%	1296
2023 Q2	$56K	Buy	+3,089	New	+$73.1K	﹤0.01%	1360
2022 Q1	–	Sell	-7,310	Closed	-$98.7K	–	2574
2021 Q4	$98.7K	Hold	7,310	–	–	﹤0.01%	2493
2021 Q3	$123K	Hold	7,310	–	–	﹤0.01%	2404
2021 Q2	$213K	Buy	7,310 +362	+5%	+$11.3K	﹤0.01%	2098
2021 Q1	$273K	Buy	6,948 +3,601	+108%	+$117K	﹤0.01%	1799
2020 Q4	$76K	Hold	3,347	–	–	﹤0.01%	2436
2020 Q3	$75.8K	Buy	+3,347	New	+$83.6K	﹤0.01%	2369

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PLRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Pliant Therapeutics (PLRX) in Q2 2024, closing a stake of 3,049 shares — an estimated $45.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PLRX in Q3 2020 and held it in 10 quarters. The position peaked at $273K in Q1 2021. 143 funds tracked by Wall St. Rank hold PLRX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Pliant Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 3,049 Pliant Therapeutics shares in Q2 2024, an estimated $45.4K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Pliant Therapeutics in Q3 2020 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Pliant Therapeutics position peaked at $273K in Q1 2021.
143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.